ArticleJournal of experimental & clinical cancer research : CR2024

A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma.

Manon Durand et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.